CD274 and melanoma: The favourable therapeutic index of PD-1/PD-L1 inhibitors and reproducible efficacy has broadened opportunities for therapy in patients with previously untreatable malignancies (for instance B-RAF Wild Type melanoma) or ineligible to traditional therapies (i.e., cisplatin-ineligible urothelial cancer).